Top news of the week: 28.07.2020.
Biotechnology, Initial public offering, Erlotinib, Smallpox, Medicine, Organism
Startups
RT @PitchBook: How has COVID-19 impacted the US VC market? Join us and industry experts from @NVCA, @SVB_Financial and @CertentInc for a webinar on the latest in fundraising, deal flow and exit activity. https://t.co/YuytWMXZOK https://t.co/LZjmPkdyzU
Open[Upcoming webinar] The evolution of US VC during the COVID-19 crisis
![[Upcoming webinar] The evolution of US VC during the COVID-19 crisis](https://files.pitchbook.com/website/images/blog/og/b/social-1_TWH.png?uq=7DaTlGdk)
Join PitchBook and NVCA for a panel discussion on how investors are responding to the current market environment as well as what opportunities and pitfalls the pandemic has introduced to VC.
Moderna nabs a BARDA billion as its kick-starts late-stage pandemic vaccine test https://t.co/CTh8IZ0dNP https://t.co/ZbXGW7qj4R
OpenModerna nabs a BARDA billion as its kick-starts late-stage pandemic vaccine test
Moderna has been handed an extra $472 million to run its phase 3 COVID-19 vaccine test.
CureVac closes $640M investment amid COVID-19 vaccine race https://t.co/KN523qAyvh https://t.co/wEBmpAzTzr
OpenCureVac closes $640M investment amid COVID-19 vaccine race
CureVac has closed a $640 million private financing round. The raising of the round, which is larger than all CureVac’s previously disclosed financings combined, comes as the biotech races ...
It’s time again—via @FiercePharma :
We're looking for 2020's Fiercest Women in Life Sciences https://t.co/KFWnMaeHVl #womeninbiotech https://t.co/Dwain4BLf4
OpenWe're looking for 2020's Fiercest Women in Life Sciences
Each year at Fierce, we spotlight women who are leading the way in biotech, pharma and medtech. Be sure to submit your nominations by 11:59 p.m. EDT Monday, Aug. 17, for consideration in ...
Coronavirus vaccine begins final phase of testing in the U.S.
https://t.co/00btIHfK5h By @TommyBeer https://t.co/Asa1tPhG0H
OpenCoronavirus Vaccine Begins Final Phase Of Testing In The U.S.
30,000 Americans have volunteered to be part of the human trial testing phase.
Borisy's EQRx bags rights to EGFR inhibitor to drive discount me-too plan https://t.co/KtV8DAU7LB https://t.co/nxDZOAPWaC
OpenBorisy's EQRx bags rights to EGFR inhibitor to drive discount me-too plan
Alexis Borisy’s EQRx has secured the ex-China rights to Hansoh Pharmaceutical’s almonertinib. The deal sets EQRx up to work the EGFR inhibitor into its plan to market me-too drugs at ...
RT @FierceBiotech: Rather than "knock out" defective genes, introduce a new gene into the body, or replace a faulty gene with a healthy copy, Encoded targets pieces of DNA that control gene expression. https://t.co/1sZus42Bjd
OpenEncoded Therapeutics bags $135M to push 'precision gene therapy' into the clinic
GW Pharma’s Epidiolex made history in 2018 when the cannabis-based treatment scored an FDA nod for Dravet syndrome, a genetic disorder marked by intractable seizures. But children with ...
Genfit is still pushing ahead with the development of elafibranor in primary biliary cholangitis (PBC), an opportunity it values at $1.5 billion, and the commercialization of its NASH diagnostic NIS4. https://t.co/pmLMYWKTWr
OpenGenfit cans phase 3 NASH trial after failing interim analysis
Genfit is set to terminate its phase 3 nonalcoholic steatohepatitis (NASH) trial after concluding it is unlikely to generate data to support approval. The action eliminates a long-time ...